Most Read

The designation is specifically for the characterisation of progressive or recurrent glioma using positron emission tomography (PET). TLX101-CDx is a PET imaging agent that targets membrane transport proteins

The company also plans to implement additional measures. This decision comes as the company seeks to extend its cash runway available and reassess its capital raising options in

The recommendation, detailed in the final draft guidance, specifically targets patients whose B-cell ALL has been resistant to treatment, has recurred post stem-cell transplant, or has relapsed for

The funding will be used for the advancement of TORL’s new antibody-drug conjugate (ADC) oncology pipeline, including the clinical development. The Series B-2 financing was led by Deep

This collaboration aims to harness Invenra’s B-Body bispecific antibody platform to advance Astellas’ research and development in antibody discovery. Invenra CEO Dr Roland Green said: “We are honoured

This approval introduces a once-daily, oral, two-drug regimen for individuals aged 12 years and above, weighing a minimum of 25kg. Dovato, which combines dolutegravir (50mg) with lamivudine (300mg),

This designation is based on results from the global multi-center Phase I/II study, WU-KONG1. The BTD was awarded following the presentation of results at the 2023 ESMO conference,

The deal focuses on a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars are gaining recognition for their potential to offer cost-effective alternatives

The funds will be channelled towards advancing multiple proprietary pipeline programmes into clinical trials, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. This significant